Drug Profile
18F FSPG
Alternative Names: 18F-FSPG; BAY94-9392; FSPGLatest Information Update: 18 Apr 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Bayer HealthCare Pharmaceuticals; Life Molecular Imaging; National Cancer Institute (USA); Stanford University
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cancer; Inflammation; Inflammatory bowel diseases
- No development reported Brain cancer
Most Recent Events
- 07 Apr 2023 Stanford University in collaboration with GE Healthcare terminates a phase II trial Inflammation (Diagnosis) in USA (IV) due to loss of funding (NCT03103490)
- 03 Nov 2021 Phase II development is still ongoing for Cancer (Diagnosis) in USA (Life Molecular Imaging website, October 2021)
- 01 Feb 2019 Stanford University plans a phase II trial for Lung cancer (Diagnosis) (NCT03824535)